MAP2K7 and nasopharyngeal carcinoma: As shown in Fig.6C–E, the treatment with U0126 and FR180204, but not that with LY294002 and MK-2206, largely blocked AT- or asarone-promoted NPC proliferation, suggesting MEK/ERK cascade rather than PI3K/Akt cascade is required for promoting NPC proliferation by AT and asarone treatment.